BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31268558)

  • 21. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
    Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
    Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2.
    Taylor J; Bulek A; Gannon I; Robson M; Kokalaki E; Grothier T; McKenzie C; El-Kholy M; Stavrou M; Traynor-White C; Lim WC; Panagiotou P; Srivastava S; Baldan V; Sillibourne J; Ferrari M; Pule M; Thomas S
    Front Immunol; 2023; 14():1119350. PubMed ID: 37334382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
    Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
    Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
    Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines.
    Ghemrawi R; Khair M; Hasan S; Aldulaymi R; AlNeyadi SS; Atatreh N; Ghattas MA
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
    Lade DM; Nicoletti R; Mersch J; Agazie YM
    Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
    Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
    J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
    Chio CM; Lim CS; Bishop AC
    Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular interactions of SHP1 and SHP2 in IL-3-signalling.
    Wheadon H; Paling NR; Welham MJ
    Cell Signal; 2002 Mar; 14(3):219-29. PubMed ID: 11812650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
    Mitra R; Ayyannan SR
    ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
    Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
    Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of protein tyrosine phosphatases Shp-2 involved in the formation of the neuromuscular junction].
    Zhao XT; Zhang Z
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1052-6. PubMed ID: 16784710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
    Butterworth S; Overduin M; Barr AJ
    Future Med Chem; 2014; 6(12):1423-37. PubMed ID: 25329198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
    Chen L; Sung SS; Yip ML; Lawrence HR; Ren Y; Guida WC; Sebti SM; Lawrence NJ; Wu J
    Mol Pharmacol; 2006 Aug; 70(2):562-70. PubMed ID: 16717135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of ellagic acid as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) for cancer treatment: In vitro and in silico study.
    Ma CH; Zhao JF; Zhang XG; Ding CH; Hao HH; Ji YH; Li LP; Guo ZT; Liu WS
    Int J Biol Macromol; 2024 Jan; 254(Pt 2):127845. PubMed ID: 37935292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.